search button

Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients

  • Authors:
    • Hyun Jung Kim
    • Jina Yun
    • Han Jo Kim
    • Kyoung Ha Kim
    • Se Hyung Kim
    • Tae Hoon Lee
    • Sang-Cheol Lee
    • Sang Byung Bae
    • Chan Kyu Kim
    • Nam Su Lee
    • Jong Ho Moon
    • Sang Heum  Park
    • Kyu Taek Lee
    • Seong Kyu  Park
    • Jong-Ho Won
    • Hee Sook Park
    • Dae Sik Hong

  • View Affiliations

  • Published online on: March 8, 2012     https://doi.org/10.3892/ol.2012.637
  • Pages: 1314-1318
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In this study, we examined the efficacy and toxicity of S-1 with cisplatin as a second-line palliative chemotherapy for gemcitabine-refractory pancreatic cancer patients. Patients who had been previously treated with gemcitabine-based chemotherapy as palliative first-line chemotherapy received S-1/cisplatin [body surface area (BSA) <1.25 m2 , S-1 40 mg/day; BSA ≤1.25 to <1.5 m2, 50 mg/day; BSA ≥1.5 m2 60 mg/day, orally, bid, daily on days 1-14 followed by a 7-day washout and cisplatin 60 mg/m2/day intravenously on day 1] every three weeks. The enrollment of 32 patients was planned, but the study was terminated early, prior to the first stage, following the enrollment of 11 patients. The median age of the patients was 56 (range, 42-74) years. Nine patients had a performance status (PS) of one. In total, there were 21 chemotherapy cycles and the median treatment duration was 21 (range, 7-96) days. Of the 11 patients, five could not be evaluated due to discontinuation prior to the response evaluation. One of the six evaluable patients achieved stable disease (9.1% in intention to treat analysis and 16.7% in per-protocol analysis), while five had progressive disease. Grade 3-4 hematological toxicities were anemia in one, neutropenia in one and thrombocytopenia in one cycle. Grade 3-4 nonhematological toxicities were fatigue in three, nausea in four, anorexia in two, diarrhea in one and peripheral neuropathy in two cycles. With a median follow-up period of 8.9 (range, 3.2-11.3) months, the median time to progression was 44 days [95% confidence interval (CI) 25.4-62.6] and the median overall survival was 81 days (95% CI 9.3-152.7). Combination chemotherapy with S-1 and cisplatin as applied in this study did not result in promising antitumor activity, a high degree of toxicity and poor compliance.
View Figures
View References

Related Articles

Journal Cover

June 2012
Volume 3 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.9
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 6.3
  • CiteScore Rank: Q2: #119/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.725
  • SCImago Journal Rank (SJR): 0.639
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Kim H, Yun J, Kim H, Kim K, Kim S, Lee T, Lee S, Bae S, Kim C, Lee N, Lee N, et al: Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients. Oncol Lett 3: 1314-1318, 2012
APA
Kim, H., Yun, J., Kim, H., Kim, K., Kim, S., Lee, T. ... Hong, D. (2012). Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients. Oncology Letters, 3, 1314-1318. https://doi.org/10.3892/ol.2012.637
MLA
Kim, H., Yun, J., Kim, H., Kim, K., Kim, S., Lee, T., Lee, S., Bae, S., Kim, C., Lee, N., Moon, J., Park, S., Lee, K., Park, S., Won, J., Park, H., Hong, D."Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients". Oncology Letters 3.6 (2012): 1314-1318.
Chicago
Kim, H., Yun, J., Kim, H., Kim, K., Kim, S., Lee, T., Lee, S., Bae, S., Kim, C., Lee, N., Moon, J., Park, S., Lee, K., Park, S., Won, J., Park, H., Hong, D."Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients". Oncology Letters 3, no. 6 (2012): 1314-1318. https://doi.org/10.3892/ol.2012.637